INTRODUCTION
============

There has been rapid growth in the number and complexity of gastrointestinal (GI) endoscopic procedures performed during the last decade\[[@b1-ce-2016-019]\]. In contrast to surgical procedures, the majority of GI endoscopic procedures are conducted outside of the operating rom. The extensive support that is available in the operating room, in terms of equipment and manpower, is typically absent.

Along with an increase in the number and complexity of endoscopic procedures, the type of sedation administered has undergone massive transformation. The sedation practices have varied across the country and within a country. For example, In the Northeastern United States, 53% of all colonoscopies were performed with the use of propofol, while in the Western region only 8% used propofol\[[@b2-ce-2016-019]\]. The same study, involving 3,168,228 colonoscopy procedures in both men and women (40 to 64 years old), also found a high incidence of all complications, both sedation and non-sedation related, in procedures performed with propofol sedation compared to non-propofol sedation. Non-propofol sedation generally consists of a short-acting benzodiazepine like midazolam and a short-acting opioid like fentanyl. All complications were increased by 13%. Specifically, these compilations included colonic perforation, hemorrhage, and stroke. In a similar study, Cooper et al. \[[@b3-ce-2016-019]\] demonstrated a higher incidence of aspiration pneumonia in patients sedated with propofol. In this population-based analysis, a total of 165,527 procedures performed in 100,359 patients, including 35,128 procedures with anesthesia services (21.2%), were analyzed. The multivariate analysis concluded that use of anesthesia services was associated with an increased risk of complication. The anesthesia services invariably included propofol for sedation.

The first nationwide survey of endoscopist-directed sedation practices in Korea found room for quality improvement\[[@b4-ce-2016-019]\]. Although the postal survey had a low response rate (22%), it found that 27.3% of all respondents performed sedation without having undergone sedation training, and 27.4% did so without any formal sedation protocols. Additionally, a large number of endoscopists reported serious sedation-related respiratory events, which are normally underestimated.

Most of the data regarding serious adverse events is patchy. A detailed analysis of such events and their eventual outcome has not been attempted. Having analyzed cardiac arrest data in a similar study, we decided to analyze all serious adverse events associated with GI endoscopic procedures \[[@b5-ce-2016-019]\].

MATERIALS AND METHODS
=====================

Institutional Review Board Approval was obtained for this study. At the hospital of the University of Pennsylvania, sedation for endoscopic procedures was provided by using either intravenous conscious sedation (IVCS) or propofol. IVCS generally consisted of a short-acting benzodiazepine like midazolam along with a short-acting opioid like fentanyl. IVCS was administered by a registered nurse under the supervision of the endoscopist who was performing the procedure, while propofol was administered by a physician anesthesiologist or a certified nurse anesthetist under the supervision of an attending anesthesiologist. Any major adverse events that occurred at any time during the hospitalization were entered into an electronic database for discussion at the Continuous Quality Improvement meeting. Additionally, adverse events that occurred during outpatient GI endoscopic procedures were entered into a local registry. The morbidity and mortality data were obtained from these sources for further analysis. Although the data analysis was retrospective, the adverse events themselves were entered soon after they had occurred. The denominator was provided by the billing section of the anesthesia and gastroenterology departments. The data included patients who underwent procedures between September 8, 2008 and May 31, 2013.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS version 23 (IBM Co., Armonk, NY, USA). The data obtained was assessed for normality using the Kolmogorov-Smirnov test. The incidence data were expressed as rate per 10,000 procedures. For factor analysis, the automated regression modeling available in SPSS was used to evaluate the contribution/relation of a factor to the outcome variable (in this case, adverse event). The available factors were combined to estimate the goodness of fit of the model for prediction of life-threatening adverse events. As the nature of sedation (propofol anesthesia or IVCS) seemed to have a significant impact on the occurrence of adverse events, we also included the type sedation as one of the determinant factors in the regression modeling (other than patient-related parameters). The results associated with a *p*\<0.05 were considered statistically significant.

RESULTS
=======

A total of 163 adverse events were reported from 73,029 procedures. These adverse events were divided into various subgroups and are presented in [Table 1](#t1-ce-2016-019){ref-type="table"} and illustrated graphically in [Fig. 1](#f1-ce-2016-019){ref-type="fig"}. As demonstrated in the table, among all adverse events, bleeding was the most common, followed by cardiorespiratory arrest, in both the propofol anesthesia and the IVCS groups. The details of the cardiorespiratory arrests were analyzed in a separate study with its own protocol and are published elsewhere \[[@b6-ce-2016-019]\]. Briefly, the cardiorespiratory arrest data included all patients who either sustained cardiac arrest and survived or who died in the hospital due to procedure-related factors. Some of these cardiac arrests were hypoventilation related, although comorbidities and postprocedural events played a considerable role.

However, this study analyzed all of the serious adverse events, not only the cardiac arrests and deaths. The relative numbers of adverse events in the individual groups (propofol anesthesia and IVCS) are shown in [Table 1](#t1-ce-2016-019){ref-type="table"}. Overall, postprocedure pain was the third most common adverse event. Although, pancreatitis ranked fourth on the list, more than 90% of these cases were associated with endoscopic retrograde cholangiopancreatography (ERCP) and with a high predilection to the propofol anesthesia group. Specific incidences of complications for esophagogastroduodenoscopy (EGD) and ERCP by individual groups are displayed in [Tables 2](#t2-ce-2016-019){ref-type="table"}, [3](#t3-ce-2016-019){ref-type="table"}. Colonoscopy is often regarded as a low risk procedure, and the complications related to it can be found in [Table 4](#t4-ce-2016-019){ref-type="table"}. The total number of adverse events stated in [Tables 2](#t2-ce-2016-019){ref-type="table"}-[4](#t4-ce-2016-019){ref-type="table"} is less than the total stated in [Table 1](#t1-ce-2016-019){ref-type="table"}. The remaining adverse events occurred in a heterogeneous group of procedures like sigmoidoscopy, liver biopsy, and fecal disimpaction. It was deemed that a separate table was unnecessary to reflect all of these adverse events.

The adverse events showing statistically significant differences in both of the groups (propofol and IVCS) are presented in [Table 5](#t5-ce-2016-019){ref-type="table"}. These events were further divided into "immediate life-threatening" and "non- life-threating." Life-threatening adverse events included cardiorespiratory arrest, significant hypoxia (needing immediate intervention), and myocardial infarction. First, automated regression modeling was used to see the goodness of fit for the following predictors: age at surgery, body mass index (BMI), Mallampatti airway class (MMP)\[[@b7-ce-2016-019]\], type of procedure, and type of sedative used (propofol vs. non-propofol). As the nature of the anesthesia (propofol anesthesia or IVCS) was deemed to have a significant impact on the adverse event outcome, type of sedation was included as one of the determinant factors in the regression modeling. The model showed overall predictability of 26.81% (*p*=0.010) for an analysis of 39 life-threatening adverse events, with the remaining 124 events labelled as non-life-threatening. Among the predictors used, a statistically significant predictive value was attained for three variables ([Table 6](#t6-ce-2016-019){ref-type="table"}). The highest predictability was seen for type of sedation, followed by the patient's American Society of Anesthesiologists (ASA) status and the type of procedure performed (in the order of strength, with predictability shown by standardized β coefficient).

Considering that EGD, ERCP, and colonoscopy are associated with different types of adverse events (due to the nature of each procedure), an analysis of adverse events associated with these procedures was performed. The results distributed by group (propofol anesthesia or IVCS) are presented in [Tables 2](#t2-ce-2016-019){ref-type="table"}-[4](#t4-ce-2016-019){ref-type="table"}. In addition, the incidence of each adverse event per 10,000 procedures is also presented. Cardiorespiratory events, including arrest (defined as any cessation of cardiac activity; however, brief, requiring cardiac compressions), was the most common adverse event in patients undergoing EGD. Postprocedure pain was the second most common adverse event. The majority of the cardiac arrests with EGD occurred during the conduct of the procedure and were hypoxemia related. Once again, the incidence of almost all adverse events was highest in the patients who were sedated with propofol. Pancreatitis was the most common adverse event in patients undergoing ERCP, followed by bleeding, with rates of 1 per 300 and 1 per 1,000 procedures, respectively. Colonoscopy had a different set of adverse events. Bleeding was the most common adverse event, followed by post procedure pain. The rate of bleeding was 1 per 1,000 procedures.

Understanding that the nature of the procedure can also be a determinant of adverse event distribution, we also compared our outcomes based on the complexity of the procedures. A comparison of the types of adverse events occurring in EGD and ERCP versus colonoscopy is presented in [Fig. 2](#f2-ce-2016-019){ref-type="fig"}.

DISCUSSION
==========

There are significant differences between the frequency of adverse events in our study and that reported in previously published studies. An often cited study by Rex et al. \[[@b8-ce-2016-019]\] was published in 2008. In this retrospective analysis of 646,080 (223,656 published and 422,424 unpublished) cases, there were 11 patients who required endotracheal intubation (ETT) and four deaths. In fact, only one death was hypoxemia related. The calculated frequencies of ETT and death were 0.17 and 0.06 per 10,000 cases, respectively. This is in sharp contrast to our own findings, in which the rates were at least 6.06 for ETT (as all patients who sustained cardiac arrest were intubated) and 1.91 for death. Like our study, the study was retrospective in nature. However, some of the data collected relied on the reporter's recall of past events, instead of relying on a storage system. Irrespective of the limitations of the study, the low frequency of reported adverse events is in sharp contrast to our own findings. It is important to note that all patients in all the patients in the Rex study received propofol from registered nurses under the supervision of a non-anesthesiologist, mainly gastroenterologists. The study population included patients of all ASA statuses and those undergoing advanced endoscopic procedures, including ERCP.

Two other recently published studies analyzed relatively larger numbers of patients. A multicenter German study published in 2014 involved 24,441 outpatients and reported no deaths or any other major adverse events. Three patients needed mask ventilation and one patient experienced laryngospasm \[[@b9-ce-2016-019]\]. None of the patients needed ETT and there were no reported deaths. It should be noted that patients undergoing advanced endoscopic procedures were excluded from this study and that propofol was administered by registered nurses under endoscopist supervision.

In an Italian, single-center retrospective study that involved 17,999 procedures performed over 8 years, all patients were sedated by anesthesia providers \[[@b10-ce-2016-019]\]. Among other events, three patients died; two from uncontrolled bleeding during the procedure and one from a bradyarrhythmia due to acute procedural distention of the bile duct. The frequency of death was 1.66 per 10,000 cases, similar to that found in our study. Cardiorespiratory adverse events were the most common, followed by aspiration. This was in contrast to our findings, which showed bleeding to be the most common adverse event. Of note, there were no deaths related to hypoxemia.

The ability to predict the likelihood of immediate life-threatening complications like cardiorespiratory arrest, myocardial ischemia, and significant hypoxia is an important aspect of our study. Most endoscopic procedures are assumed to be minor and of low risk. In spite of the limitations of the predictive model used, the model suggests the "red flags" for the likelihood of life-threatening complications. These include higher ASA grade (from III onwards), propofol-based sedation, and ERCP. Despite the model's low accuracy (26%) for predicting such events, it can be used to alert the endoscopist and to reduce the risks. Interestingly, BMI had a negative correlation with these events (although it failed to achieve statistical significance, and we reported a similar finding in a previous study) \[[@b1-ce-2016-019]\]. This result may seem contrary to contemporary thinking and may be attributed to the fact that most anesthesia providers anticipate airway related problems in obese patients and take extra caution during the procedure. Additionally, obese patients often receive a nasal airway; thus, preventing further airway-related adverse events.

The American Society for Gastrointestinal Endoscopy has issued guidelines, with the most recent issued in 2012. In these guidelines, titled "Adverse events of upper GI endoscopy," cardiopulmonary adverse events are stated to be responsible for 60% of all events during upper GI endoscopic procedures \[[@b11-ce-2016-019]\]. Although this may be true when all adverse events are taken into consideration, in our analysis, bleeding was the most common, followed by cardiorespiratory events. Moreover, only one of the five studies cited in the guidelines was published after 2001 \[[@b12-ce-2016-019]\]. Inclusion of more current publications might change the results. Recent changes in the landscape of endoscopy practice with regard to sedation management and procedure complexity are worthy of note. Propofol is used extensively for sedation in modern endoscopy practice. The complexity of the procedures has seen a significant change. The population demographics have changed, with elderly and obese patients forming a significant minority \[[@b1-ce-2016-019]\]. In our analysis, cardiopulmonary events contribute to less than 40% of all adverse events. However, these events are severe and are often associated with cardiac arrest and death. As mentioned, the details are available for interested readers elsewhere \[[@b6-ce-2016-019]\].

One disturbing finding of our study is an increase in the frequency of many types of adverse events in the group of patients sedated with propofol. The cardiac arrests, their mechanisms, and their outcomes were analyzed as a separate study and are being published elsewhere. Respiratory adverse events related to sedation played a significant role in patients who experienced periprocedural cardiac arrest. However, establishing a direct relationship between non-respiratory adverse events and periprocedural cardiac arrest is more difficult. It is conceivable that propofol sedation was used predominantly in patients with higher morbidity. Patients sedated with propofol had an increased incidence of bowel perforation, pancreatitis, post procedure pain, febrile reactions, and iatrogenic adverse events ([Table 5](#t5-ce-2016-019){ref-type="table"}). Cooper et al. \[[@b3-ce-2016-019]\] reported an increase in the incidence of colonic perforation in patients undergoing colonoscopy with propofol sedation. Similar findings are reported by other investigators \[[@b13-ce-2016-019]\]. One proposed mechanism is the diminished ability of the operator to appreciate the amount of force exerted with the endoscope due to diminished patient feedback.

Some practices might be specific to our center and might have contributed to a change in the types of adverse events seen. The incidence of hypoxemia in patients sedated with propofol is low, likely due to a proactive approach to airway management \[[@b1-ce-2016-019],[@b14-ce-2016-019]\], even in patients with morbid obesity and sleep apnea. The use of a core group of anesthesiologists in the endoscopy area has facilitated the reduction of these events and shown associated cost savings \[[@b15-ce-2016-019]\]. Some of the patients had significant comorbidity, such as implanted devices for ventricular assistance. However, the incidence of sedation-related adverse events even in this group was negligible due to modified airway management technique \[[@b16-ce-2016-019]\]. The experiences of many other centers with advanced endoscopic procedures conducted with propofol sedation are in contrast to our experience \[[@b17-ce-2016-019],[@b18-ce-2016-019]\]. Variation in the method of airway management might explain these differences.

Lastly, our findings are in sharp contrast to those of studies involving non-anesthesiologist administered propofol. A meta-analysis comparing the adverse events in patients administered propofol by anesthesia providers to those in patients administered propofol by non-anesthesia providers is available \[[@b19-ce-2016-019]\]. The study involved only advanced endoscopic procedures and showed a very low incidence of both hypoxemia and airway intervention rates when propofol was administered by non-anesthesia providers. However, in 25 of the 26 studies included in the meta-analysis the corresponding author was a gastroenterologist. Interestingly, all of the studies were published in gastroenterology journals. Only a well-designed, prospective, randomized controlled trial comparing the safety of propofol administration by the two groups can answer this question. Considering the debate involves patient safety as well as significant potential cost savings, it is important to explore the issue further.

Being retrospective in nature, the current study has certain limitations. When the data are entered into the charts, the clinician is unlikely to consider the likelihood of the data being analyzed at a future date. Incomplete data and the unavailability of important information pose unique problems. However, the large number of subjects is likely to negate this particular drawback. The same limitation is likely to have played a role in the regression modeling used in our analysis. Only a limited number of patient-related factors were available, and the adverse event severity in the charts was neither presented consistently nor standardized. In predictive models, one cannot negate the presence of undocumented factors that might have contributed to an adverse event.

Rather than investigate the contribution of causative factors for adverse events such as sepsis and pneumonia, we chose to investigate the contribution of the universally available patient characteristics age, BMI, ASA status, and MMP grade.

In conclusion, it is likely that the incidence and nature of the adverse events that occur during GI endoscopic procedures have changed over the last decade. Changing demographics and comorbidities of the patient population, in association with increasing technical complexity of the interventions performed, might explain this. Although the extensive use of propofol has increased patient satisfaction and the acceptability of GI endoscopic procedures, many types of adverse events occur more frequently in the subset of patients that receives propofol. A large, multicenter, prospective, randomized controlled trial might help to understand the mechanisms of these adverse events and their relationship to propofol use, if any.
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###### 

A Simplified Presentation of All 163 Adverse Events Associated with 73,029 Procedures Endoscopic Procedures

  Adverse event                  Frequency             
  ------------------------------ ----------- ---- ---- -----
  1\. Bleed                      21          18   12   51
  2\. Cardiorespiratory arrest   16          4    1    21
  3\. Postprocedural pain        10          6    4    20
  4\. Pancreatitis               16          1    0    17
  5\. Arrhythmias                5           2    1    8
  6\. Febrile reaction           4           1    1    6
  7\. Non-cardiac chest pain     2           4    0    6
  8\. Perforation                3           1    1    5
  9\. Hypoxia                    4           0    0    4
  10\. Iatrogenic                3           1    0    4
  11\. Hemodynamic               1           2    0    3
  12\. Myocardial infarction     2           0    0    2
  13\. Miscellaneous             1           0    1    2
  14\. Obstruction               2           0    0    2
  15\. Tooth break               2           0    0    2
  16\. Anaphylaxis               0           0    1    1
  17\. Aspiration pneumonia      1           0    0    1
  18\. Cognitive dysfunction     1           0    0    1
  19\. Dyspnoea                  0           0    1    1
  20\. GI obstruction            0           0    1    1
  21\. Seizures                  0           1    0    1
  22\. Sore throat               1           0    0    1
  23\. Stricture                 1           0    0    1
  24\. Stridor                   1           0    0    1
  25\. Syncope                   0           1    0    1
  Total                          97          42   24   163

A, anesthesia provider administered sedation; S, gastrointestinal endoscopist directed sedation; GI, gastrointestinal.

###### 

Frequency and Incidence (per 10,000 Procedures) of Selected Adverse Events in Patients Undergoing Esophagogastroduodenoscopy

  Adverse event                                                            A (n=14,534)   S (*n*=16,907)   NA   Total (*n*=31,441)            
  ------------------------------------------------------------------------ -------------- ---------------- ---- -------------------- --- ---- --------
  Cardiorespiratory arrest^[a)](#tfn1-ce-2016-019){ref-type="table-fn"}^   13             8.940            0    0                    1   14   4.433
  Postprocedure pain                                                       4              2.751            3    1.770                3   10   3.167
  Bleed                                                                    3              2.063            3    1.770                2   8    2.533
  Non-cardiac chest pain                                                   2              1.375            2    1.180                0   4    1.267
  Arrhythmias                                                              2              1.375            0    0                    1   3    0.950
  Hypoxia                                                                  3              2.063            0    0                    0   3    0.950
  Perforation                                                              3              2.063            0    0                    0   3    0.950
  Iatrogenic                                                               2              1.375            0    0                    0   2    0.633
  Myocardial infarction                                                    2              1.375            0    0                    0   2    0.633
  Pancreatitis                                                             2              1.375            0    0                    0   2    0.633
  Tooth break                                                              2              1.375            0    0                    0   2    0.633
  Anaphylaxis                                                              0              0                0    0                    1   1    0.317
  Cognitive dysfunction                                                    1              0.688            0    0                    0   1    0.317
  Hemodynamic                                                              0              0                1    0.590                0   1    0.317
  Obstruction                                                              1              0.688            0    0                    0   1    0.317
  Seizures                                                                 0              0                1    0.590                0   1    0.317
  Sore throat                                                              1              0.688            0    0                    0   1    0.317
  Stricture                                                                1              0.688            0    0                    0   1    0.317
  Total                                                                    42             28.883           10   6                    8   60   19.000

A, anesthesia provider administered sedation; S, gastrointestinal endoscopist directed sedation; NA, not available.

Statistically significant different values using chi-square test (*p*\<0.05) are marked.

###### 

Frequency and Incidence (per 10,000 Procedures) of Selected Adverse Events in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography

  Adverse event                                                    A (*n*=3,694)   S (*n*=1,545)   Total (*n*=5,239)                 
  ---------------------------------------------------------------- --------------- --------------- ------------------- -------- ---- --------
  Pancreatitis^[a)](#tfn2-ce-2016-019){ref-type="table-fn"}^       14              37.900          1                   6.472    15   28.631
  Bleed^[a)](#tfn2-ce-2016-019){ref-type="table-fn"}^              5               13.535          0                   0        5    9.544
  Febrile reaction^[a)](#tfn2-ce-2016-019){ref-type="table-fn"}^   4               10.828          0                   0        4    7.635
  Cardiorespiratory arrest                                         2               5.414           1                   6.472    3    5.726
  Postprocedural pain                                              2               5.414           0                   0        2    3.818
  Arrhythmias                                                      1               2.707           0                   0        1    1.909
  Hypoxia                                                          1               2.707           0                   0        1    1.909
  Iatrogenic                                                       1               2.707           0                   0        1    1.909
  Miscellaneous                                                    1               2.707           0                   0        1    1.909
  Total                                                            31              83.920          2                   12.945   33   62.989

A, anesthesia provider administered sedation; S, gastrointestinal endoscopist directed sedation.

Statistically significant different values using chi-square test (*p*\<0.05) are marked.

###### 

Frequency and Incidence (per 10,000 Procedures) of Selected Adverse Events in Patients Undergoing Colonoscopy

  Adverse event              A (*n*=9,767)   S (*n*=23,536)   NA   Total (*n*=33,303)             
  -------------------------- --------------- ---------------- ---- -------------------- ---- ---- --------
  Bleed                      13              13.310           13   5.523                10   36   10.810
  Postprocedural pain        3               3.072            2    0.850                1    6    1.802
  Arrhythmias                2               2.048            2    0.850                0    4    1.201
  Cardiorespiratory arrest   1               1.024            2    0.850                0    3    0.900
  Febrile reaction           0               0                1    0.425                1    2    0.601
  Hemodynamic                1               1.024            1    0.425                0    2    0.601
  Perforation                0               0                1    0.425                1    2    0.601
  Aspiration pneumonia       1               1.024            0    0                    0    1    0.300
  Dyspnoea                   0               0                0    0                    1    1    0.300
  GI obstruction             0               0                0    0                    1    1    0.300
  Non-cardiac chest pain     0               0                1    0.425                0    1    0.300
  Obstruction                1               1.024            0    0                    0    1    0.300
  Stridor                    1               1.024            0    0                    0    1    0.300
  Total                      23              23.549           23   9.772                15   61   18.317

None of the values were statistically different in any of the groups.

A, anesthesia provider administered sedation; S, gastrointestinal endoscopist directed sedation; NA, not available; GI, gastrointestinal.

###### 

Comparison of Frequency of Selected Adverse Events Showing Statistically Significant Difference between Propofol and Non-Propofol Sedation

                       Propofol   Intravenous conscious sedation   *p*-value (chi-square test)
  -------------------- ---------- -------------------------------- -----------------------------
  Cardiac arrest       6.069      0.666                            \<0.0001
  Pancreatitis         5.698      0.222                            \<0.0001
  Postprocedure pain   3.561      1.322                            \<0.0001
  Febrile reaction     1.780      0.222                            \<0.0001
  Iatrogenic           2.137      0.222                            \<0.0001

###### 

Regression Modelling for Predictors of "Immediate Life Threatening Complications"

  Factor                                                         Life threatening vs. Non-life threatening   
  -------------------------------------------------------------- ------------------------------------------- -------
  BMI                                                            --0.179                                     0.103
  MMP                                                            0.188                                       0.112
  ASA^[b)](#tfn4-ce-2016-019){ref-type="table-fn"}^              0.243                                       0.032
  Age at surgery                                                 0.056                                       0.639
  Procedure type^[c)](#tfn5-ce-2016-019){ref-type="table-fn"}^   0.210                                       0.041
  Sedation type^[d)](#tfn6-ce-2016-019){ref-type="table-fn"}^    0.428                                       0.002
  Overall predictability                                         26.81% (*p*=0.001)                          

BMI, body mass index; MMP, Mallampatti airway class; ASA, American Society of Anesthesiologists.

The strength of association is shown by "β coefficient" and the negative β coefficient denotes a negative relation between factor and outcome (life threatening complications included cardiorespiratory arrest, significant hypoxia \[needing immediate intervention\] and myocardial infarction);

American Society of Anaesthesiologists status 3 and above is associated with higher risk life threatening events;

Endoscopic retrograde cholangiopancreatography is associated with higher risk of life threatening events;

Propofol sedation is associated with higher risk of life threatening events.
